SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI
CCSI 29.07+1.3%1:50 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Clayleas who wrote (2224)5/21/1998 9:31:00 PM
From: Cacaito  Read Replies (4) of 5736
 
Most pediatricians will not buy this type of device. They just do not need it.

Emergency rooms will have little use for these devices, one per hospital more than enough. Granted big institutions will buy 2 or 3.

Not every bilirubin is the same, one needs total,direct and indirect bilirubin. The Colormate can not make this difference.

Even if SPRX takes one year to come to market they will be competition sooner or later. At least in the international market they "are already shipping".

Almost of no use for children or adults, the Colormate will tell what the eyes could tell. If one needs more data traditional blood test for total, direct and indirect bilirubin is a must, the Colormate can not do it.

Newborn babies first week of life are the main market, after the first week of life Colormate will be of little use.

The other uses are on development, they will add to the share price as they show progress.

Do they work on glucose measurement technology? If they are then they have a big potential. Non invasive glucose testing is a true $ billion market. Can CCSI do glucose?

The disposables business increases revenues, but it increases costs to the user.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext